Prevalence of adverse drug reactions among MDR-TB patients with different anti  tubercular regimens

P Narayana Swamy; V Santhosh Kumar

doi:10.53730/ijhs.v6nS4.11964

Authors

P Narayana Swamy
swamy.cool99@gmail.com
Research scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Pallavaram, Chennai - 600117
V Santhosh Kumar Professor & Research Supervisor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Pallavaram, Chennai - 600117

Keywords:

tuberculosis, adverse drug reactions, multidrug reaction

Abstract

Aim: The main aim of this study is to monitor the adverse drug reactions among the patients treated with different regimens for MDR-TB. Materials and Methods: Patients who were diagnosed with MDR-TB of either gender and with an age of above 18 years were included in this study. The causality assessment of the ADRs was done by using the Naranjo’s scale and according to this scale, the ADRs were classified based on the scores into definite ADRs (≥9), probable ADRs (5-8), possible ADRs (1-4) and doubtful ADRs (0). Results: Among the 300 study participants, 129 (43%) were observed to be with various adverse drug reactions in this study. In this study, most of the ADRs were observed to be with gastrointestinal related (37.2%) followed by nausea & vomiting (20.2%), According to the Naranjo’s scale, the causality assessment was done and it was observed that among the 129 cases. Conclusion: According to the Naranjo’s causality assessment, most of the ADRs were possible ADRs followed by probable, most of the ADRs were observed to be with moderate severity followed by mild severity.

Downloads

Download data is not yet available.

References

Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, et al. DOTS-Plus for patients with multidrug-resistant tuberculosis in India: early results after three years. Ind J of Che Disea and All Scienc. 2007;49(2):75.

Bloss E, Kukša L, Holtz TH, Riekstina V, Skripčonoka V, Kammerer S, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int J tuberc lung dis. 2010 Mar 1;14(3):275-81.

Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; New Delhi. Central TB Division. Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India. New Delhi: May 2012.

Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J tuberc lung dis. 2001;5(7):648-55.

Hire R, Kale AS, Dakhale GN, Gaikwad N. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in Central India. Medit J of Hem and Infec Disea. 2014;6(1).

Jain K, Desai M, Dikshit RK. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother. 2014;5(2):145-9.

Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. The Ind J of Med Resea. 2011 May;133(5):529.

Kapadia VK, Tripathi SB. Analysis of 63 patients of MDR TB on DOTS plus regimen: An LG hospital, TB Unit, Ahmadabad experience. Guj Med J. 2013;68(2);52-7.

López-Quiroz, D. C., & Yánez-Balarezo, F. A. (2022). Drug addiction in the academic performance of high school students in a rural educational unit. International Research Journal of Management, IT and Social Sciences, 9(4), 682-689. https://doi.org/10.21744/irjmis.v9n4.2151

National and state statistics TB statistics for India. Organisation WH, Control GT. MDRTB Statistics for India. 2015:1-9.

Prasad R. Management of multi-drug resistant tuberculosis Practitioner’s view point. Indian Journal of Tuberculosis. 2007;54:3-11.

Singh BD, Ghulam H, Kadri SM, Qureshi W, Kamili MA, Singh H et al. Multidrug-Resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries. 2010;4(1):19-23.

Singh R, Gothi D, Joshi JM. Multidrug Resistant Tuberculosis: Role of Previous Treatment with Second Line Therapy on Treatment Outcome. Lung India. 2007;24:54-7.

Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven-year DOTS-Plus pilot experience in India: Results, constraints and issues. The International Journal of Tuberculosis and Lung Disease. 2009;13:976-81.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938

Törün T, Güngör G, Özmen I, Bölükbaşı Y, Maden E, Bıçakçı B, Atac G, Sevim T, Tahaoğlu K. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J tuberc lung dis. 2005 Dec 1;9(12):1373-7.

Vivas, F. E. V., Cuello, R. L. C., Macías, D. M., & Rosado, G. P. (2017). Elaboration of essential oil from the oregano for medicinal use sheet. International Journal of Physical Sciences and Engineering, 1(1), 81–87. https://doi.org/10.21744/ijpse.v1i1.22

Wai yew W, Kuen CC, Hung CC, Cheeuk MTC. Outcomes of patients with multidrug resistant pulmonary tuberculosis treated with Ofloxacin/Levofloxacin containing regimens. Chest. 2000;177:744-51.

WHO. Global Tuberculosis Report 2016. [Internet]. 2016. Available at: rchandq=intitle:No+Title#0http://scholar.google.com/scholar?hl=enandbtnG=Sea